Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Studying samples of blood and tissue in the laboratory from women receiving
doxorubicin and trastuzumab for breast cancer may help doctors learn more about changes that
occur in DNA and identify biomarkers for increased risk of cardiac effects.
PURPOSE: This clinical trial is studying side effects involving the heart in women with
breast cancer receiving doxorubicin and trastuzumab.
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center